In multiple sclerosis, the myelin sheath is heavily damaged. New evidence suggests that inhibitory signals mediated by the Notch pathway suppress remyelination (pages 1115–1121).
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
An enhanced triple fluorescence flow-cytometry-based assay shows differential activation of the Notch signaling pathway by human papillomavirus E6 proteins
Scientific Reports Open Access 22 February 2022
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Renee Lucas
References
Lassmann, H., Brück, W. & Lucchinetti, C. Heterogeneity of multiple sclerosis pathogenesis: Implications for diagnosis and therapy. Trends Mol. Med. 7, 115–121 (2001)
John, R. et al. Multiple sclerosis: Re-expression of a developmental pathway that restricts oligodendrocyte maturation. Nature Med. 8, 1115–1121 (2002).
Wolswijk, G. Oligodendrocyte precursor cells in the demyelinated multiple sclerosis spinal cord. Brain 125, 338–349 (2002).
Franklin, R.J.M. Why does remyelination fail in multiple sclerosis? Nature Rev. Neurosci. 3, 705–714 (2002).
Chang, A., Tourtellotte, W.W., Rudick, R. & Trapp, B.D. Premyelinating oligodendrocytes in chronic lesions of multiple sclerosis. N. Engl. J. Med. 346, 165–173 (2002).
Charles, P. et al. Re-expression of PSA-NCAM by demyelinated axons: An inhibitor of remyelination in multiple sclerosis? Brain 125, 1972–1979 (2002).
Gorelik, L. & Flavell, R.A. Transforming growth factor-β in T-cell biology. Nature Rev. Immunol. 2, 46–53 (2002).
Wiendl, H. & Hohlfeld, R. Therapeutic approaches in multiple sclerosis: Lessons from failed and interrupted treatment trials. BioDrugs. 16, 183–200 (2002).
Osborne, B. & Miele, L. Notch and the immune system. Immunity 11, 653–663 (1999).
Butzkueven, H. et al. LIF receptor signaling limits immune-mediated demyelination by enhancing oligodendrocyte survival. Nature Med. 8, 613–619 (2002).
Linker, R.A. et al. CNTF is a major protective factor in demyelinating CNS disease: A neurotrophic cytokine as modulator in neuroinflammation. Nature Med. 8, 620–624 (2002).
Lucchinetti, C.F., Noseworthy, J.H. & Rodriguez, M. Promotion of endogenous remyelination in multiple sclerosis. Mult. Scler. 3, 71–75 (1997).
Halfpenny, C., Benn, T. & Scolding, N. Cell transplantation, myelin repair, and multiple sclerosis. Lancet Neurol. 1, 31–40 (2002)
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hohlfeld, R. Myelin failure in multiple sclerosis: Breaking the spell of Notch. Nat Med 8, 1075–1076 (2002). https://doi.org/10.1038/nm1002-1075
Issue Date:
DOI: https://doi.org/10.1038/nm1002-1075
This article is cited by
-
An enhanced triple fluorescence flow-cytometry-based assay shows differential activation of the Notch signaling pathway by human papillomavirus E6 proteins
Scientific Reports (2022)
-
Gestational Hypothyroxinemia Imprints a Switch in the Capacity of Astrocytes and Microglial Cells of the Offspring to React in Inflammation
Molecular Neurobiology (2017)
-
Stem cell therapy for central nervous system demyelinating disease
Current Neurology and Neuroscience Reports (2005)
